Telix Pharmaceuticals TLX
NASDAQ TLX
$11.34 -0.28 (-2.41%)
At close: Sep 29, 2026 · 4:00 PM EDT

Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2026)

Updated

Telix Pharmaceuticals (TLX) recorded Non-Current Debt of $504.88 million in the quarter ended Jun 30, 2026.

Analysis

Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2026) Analysis & Trends

As of Dec 31, 2025, Telix Pharmaceuticals reported Non-Current Debt of $391.91 million, up 14.7% from the prior year.

  • Across earlier years, Non-Current Debt came in at $341.81 million in the year ended Dec 31, 2024 and $5.95 million in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 37.34 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 62.48 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -108.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 23.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Telix Pharmaceuticals 3.94 Bn 2.88 Bn - 504.88 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 504.88 Mn
Dec 31, 2025 391.91 Mn
Dec 31, 2024 360.87 Mn
Dec 31, 2023 5.34 Mn
API Access

Telix Pharmaceuticals Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=TLX&period=max&api_key=YOUR_API_KEY